For a company long viewed as a staid dividend payer, IBM has been anything but predictable in recent weeks. After a violent June correction that saw the stock shed 15 percent from its high, shares have bounced back sharply, climbing 2.73 percent in the latest session to trade at EUR 254.15. That rally has brought the stock within striking distance of its 50-day moving average near EUR 220 and pushed its relative strength index to 63.8 — a level that edges into overbought territory. But the real test arrives on July 22, when management reports second-quarter results and investors will finally see whether the underlying business supports the recent price action.
The June sell-off was a pure sentiment event, with no direct downgrade from IBM itself. The catalyst came from competitor Accenture, which lowered its 2026 revenue forecast and reignited fears that generative AI tools could cannibalize traditional IT services. IBM’s own research on AI sovereignty added to the unease: 91 percent of executives admitted they do not fully understand their AI dependencies, raising the risk that major cloud projects could be delayed. The market interpreted these signals as a warning for IBM’s consulting and cloud units, and the stock dropped from its peak quickly. Yet no earnings warning was issued — the sell-off was a mood-driven correction on an overbought stock.
On the upside, a series of strategic developments provides the bull case. JPMorgan upgraded IBM to Overweight in late June, citing strong software and AI execution. Management has guided for software revenue growth of more than 10 percent this year, and a recent FedRAMP authorization for 11 of IBM’s AI solutions — now available on Amazon’s government cloud — has quadrupled the company’s certified public-sector AI portfolio in just 12 months. IBM is also targeting the highest U.S. government security clearance by late 2026 or early 2027, a move that could open the door to sensitive defense and intelligence contracts. If the quarterly numbers confirm double-digit software growth, the rally could extend.
The quantum computing story adds a layer of long-term optionality. IBM is pouring more than USD 10 billion into the technology over five years, aiming to deliver the first fault-tolerant quantum computer by 2029. The company already has more than 90 quantum systems installed globally and a partner ecosystem of over 325 organizations, including enterprises, startups and government agencies. A recent milestone at the Cleveland Clinic saw researchers successfully simulate a complex protein structure on IBM hardware. And in June, IBM released an open-source extension that can detect errors directly in quantum circuits — a quiet but critical step toward real-world reliability. The earnings call will provide an opportunity for management to update this roadmap.
Should investors sell immediately? Or is it worth buying IBM?
But the bear case is equally weighty. The stock has advanced only 2.89 percent over the past 12 months, and the annualized 30-day volatility sits above 60 percent — hardly the profile of a steady blue chip. The RSI reading of 63.8 suggests the recent rebound may have been a technical reflex rather than a fundamental re-rating. If the software growth disappoints or the consulting business shows cracks, the overbought condition could trigger sharp profit-taking. A break below the 200-day moving average at EUR 236 would open the door to further downside.
Technically, the stock is caught between two key levels. Support from the 50-day average around EUR 220 held during the June dip, and a clean hold above that line would keep the medium-term uptrend intact. On the upside, resistance looms at the annual high of EUR 292.85 — a level that seemed unreachable just weeks ago. The average analyst price target of EUR 258 sits just above the current price, leaving limited room for error.
All eyes are now on July 22. If IBM delivers software revenue growth above 10 percent and offers concrete updates on quantum commercialization, the rally has room to run. If the numbers underwhelm, the stock’s technical exhaustion will provide ample justification for a pullback. The next move depends entirely on which version of IBM shows up.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from July 1 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 1.
IBM: Buy or sell? Read more here...
